## **SECTION V:** 510(K) SUMMARY:

## 510(k) Summary

FemSpec Disposable Vaginal Speculum

## **Date Prepared:**

This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

#### A. Submitter

FemSpec

220 Halleck Street, Suite 120 San Francisco, CA 94129-0450

## **B.** Company Contact

Gerald Jay Sanders, CEO

#### C. Device Name

Trade Name:

FemSpec Disposable Vaginal Speculum

Common Name:

Disposable Vaginal Speculum

Classification Name:

Non-metal Vaginal Speculum

Classification:

Class II per 21 CFR 884.4530

#### D. Predicate Devices

K012535 - Doctors Research Group SoftSpec Vaginal Speculum

## E. Description of Device

The FemSpec disposable vaginal speculum consists of a soft plastic inflatable bladder, which once inserted into the vagina is inflated to uniformly press the vaginal wall open. Once inflated the bladder generates an annular space for diagnostic procedures of the cervix.

#### D. Intended Use

The FemSpec disposable vaginal speculum is indicated for diagnostic procedures of the cervix.

## E. Comparison of Technological Characteristics

The basic technology, design, mode of operation, materials of construction and intended use of the FemSpec<sup>TM</sup> disposable vaginal speculum is substantially equivalent to the predicate device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 2 3 2004

Mr. Gerald Jay Sanders CEO FemSpec L.L.C. 220 Halleck Street, Suite 120B P.O. Box 29450 SAN FRANCISCO CA 94129 Re: K041757

Trade/Device Name: FemSpec<sup>™</sup> Disposable

Vaginal Speculum

Regulation Number: 21 CFR 884.4530 Regulation Name: Obstetric-gynecologic

specialized manual instrument

Regulatory Class: II Product Code: 85 HIB Dated: October 19, 2004 Received: October 20, 2004

## Dear Mr. Sanders:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

| 21 CFR 876.xxxx                             | (Gastroenterology/Renal/Urology) | 240-276-0115 |
|---|----------------------------------|--------------|
|   | (Obstetrics/Gynecology)          | 240-276-0115 |
|   | •                                | 240-276-0120 |
|   | (130                             | 240-276-0100 |
| 21 CFR 884.xxxx<br>21 CFR 892.xxxx<br>Other | (Radiology)                      | 240-276-0120 |

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Nancy C. Brogdon

Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# Indications for Use

| 510(k) Number (if known):                             |                            |   |
|---|----------------------------|---|
| Device Name: <u>FemSpec<sup>TM</sup> Disposable</u>   | e Vaginal Speculum         |   |
| ndications for Use:                                   |                            |   |
| The FemSpec <sup>TM</sup> disperprocedures of the cer |                            | lum is indicated for diagnostic             |
|   |                            |   |
|   |                            |   |
|   |                            |   |
|   |                            |   |
|   |                            |   |
| Prescription Use: X (Part 21 CFR 801 Subpart D)       | AND/OR                     | Over-The-Counter Use:(21 CFR 801 Subpart C) |
| (PLEASE DO NOT WRITE BELO                             | OW THIS LINE-CO<br>NEEDED) | NTINUE ON ANOTHER PAGE OF                   |
| Concurrence of CT                                     | ORH Office of Devi         | ce Evaluation (ODE)                         |

Emin de Lynn Abdominal, KO41757